Health Technology
Hisamitsu Pharmaceutical Co., Inc.
In the news
- Hisamitsu's 9-month operating profit likely down 11% Dec 26, 2017
- Hisamitsu's interim operating profit seen down 3% Sep 23, 2017
- Tourists to Japan now spending more on the cheap Aug 29, 2017
- Hisamitsu's quarterly profit seen hurting on competition from generics Jun 23, 2017
- Hisamitsu Pharma profit seen 13% slimmer Jun 28, 2016 See more articles on Hisamitsu Pharmaceutical Co., Inc.
Business Summary
Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, and Keplat brands. It also provides ethical pharmaceuticals, over- the-counter drugs, medical devices, health supplements, and topical analgesic products. The company was founded by Nihei Hisamitsu in 1847 and is headquartered in Tosu, Japan.
Financial Highlights
| Feb 2021 | JPY | USD |
| Revenue | 114,510M | 1,080.68M |
| Gross Profit | 69,173M | 652.81M |
| Operating income | 10,672M | 100.71M |
| Income before tax | 12,197M | 115.10M |
| Net income | 9,251M | 87.30M |
| EBITDA | 14,751M | 139.21M |
| Diluted EPS | 113.10 | 1.06 |
| Dividends Per Share | 83.50 | 0.78 |
| Total Assets | 299,861M | 2,814.53M |
| Total liabilities | 46,048M | 432.21M |
| Total equity | 252,299M | 2,368.11M |
| Operating cash flow | 5,289M | 49.91M |
| Currency in JPY | Currency in USD |
Historical Data
| Feb 2017 | Feb 2018 | Feb 2019 | Feb 2020 | Feb 2021 | |
| Revenue | 145,925M | 147,870M | 143,408M | 140,992M | 114,510M |
| Gross Profit | 91,840M | 92,182M | 88,681M | 87,604M | 69,173M |
| Operating income | 26,306M | 26,346M | 22,280M | 22,729M | 10,672M |
| Income before tax | 29,984M | 27,694M | 25,673M | 26,155M | 12,197M |
| Net income | 20,395M | 19,120M | 19,204M | 18,694M | 9,251M |
| EBITDA | 33,674M | 32,351M | 28,022M | 26,980M | 14,751M |
| Diluted EPS | 241.14 | 228.34 | 229.85 | 227.29 | 113.10 |
| Dividends Per Share | 81.50 | 82 | 82.50 | 83 | 83.50 |
| Total Assets | 278,820M | 299,913M | 295,786M | 307,401M | 299,861M |
| Total liabilities | 49,611M | 54,681M | 47,154M | 56,652M | 46,048M |
| Total equity | 228,108M | 244,000M | 247,334M | 249,276M | 252,299M |
| Operating cash flow | 19,910M | 30,453M | 15,772M | 27,395M | 5,289M |
| Feb 2017 | Feb 2018 | Feb 2019 | Feb 2020 | Feb 2021 | |
| Revenue | 1,347.79M | 1,327.30M | 1,298.05M | 1,293.38M | 1,080.68M |
| Gross Profit | 848.25M | 827.44M | 802.69M | 803.63M | 652.81M |
| Operating income | 242.96M | 236.48M | 201.66M | 208.50M | 100.71M |
| Income before tax | 276.93M | 248.58M | 232.37M | 239.93M | 115.10M |
| Net income | 188.37M | 171.62M | 173.82M | 171.48M | 87.30M |
| EBITDA | 311.02M | 290.38M | 253.63M | 247.50M | 139.21M |
| Diluted EPS | 2.22 | 2.04 | 2.08 | 2.08 | 1.06 |
| Dividends Per Share | 0.75 | 0.73 | 0.74 | 0.76 | 0.78 |
| Total Assets | 2,492.02M | 2,810.67M | 2,657.07M | 2,849.86M | 2,814.53M |
| Total liabilities | 443.41M | 512.45M | 423.58M | 525.21M | 432.21M |
| Total equity | 2,038.77M | 2,286.67M | 2,221.82M | 2,310.99M | 2,368.11M |
| Operating cash flow | 183.89M | 273.35M | 142.75M | 251.30M | 49.91M |
Valuation Measures
| Feb 2021 | |
| PER | 58.65 |
| ROA | 3.04% |
| ROE | 3.68% |
| Operating margin | 9.31% |
| Profit margin | 8.07% |
Key executives
- President & Representative Director: Kazuhide Nakatomi
- Director, Executive Officer, Manager-Finance & IR: Shinichiro Takao
- Senior Executive Officer, GM-R&D: Takaaki Terahara
- Director, Manager-Legal Affairs & Head-Compliance: Nobuo Tsutsumi
- MD, Executive Officer & Head-Operations: Tetsuo Akiyama
Shareholders
- Government of Japan (5.7%)
- Nishi Nippon City Bank Pension Fund (5.1%)
- Bank of Tokyo Mitsubishi UFJ Pension Fund (5.0%)
- Nippon Life Insurance Co. (4.5%)
- Hisamitsu Pharmaceutical Co., Inc. (3.9%)
- Fukuoka Financial Group, Inc. (3.9%)
- The Bank of Saga Ltd. (2.7%)
- Hisamitsu Pharmaceutical Business Association (2.7%)
- Sumitomo Mitsui Banking Pension Fund (2.4%)
- Mitsubishi UFJ Financial Group, Inc. (2.1%)
Contact Details
- Website:http://www.hisamitsu.co.jp
- Phone: +81.942.83.2101
Related Companies
- Hisamitsu Italia Srl
- Hisamitsu Agency Co., Ltd
- Hisamitsu Pharmaceutical (Hong Kong) Co., Ltd.
- Hisamitsu Pharmaceutical (China) Co., Ltd.
- Nakatomi Memorial Foundation
- Hisamitsu Pharmaceutical Co., Ltd
- Hisamitsu Farmaceutica do Brasil Ltda.
- Hisamitsu Vietnam Pharmaceutical Co., Ltd.
- PT Hisamitsu Pharma Indonesia
- Hisamitsu UK Ltd.
- Hisamitsu Pharmaceutical Business Association
- Hisamitsu Pharmaceutical Tech Consulting (Beijing) Co., Ltd.
- CRCC Media Co., Ltd.
- Hisamitsu America, Inc.
- Saga City-Vision Co., Ltd.
- Hisamitsu U.S., Inc.
- SSP Co. Ltd. /Ethical Medicine Division/
- Taiyo Co., Ltd
- Noven Pharmaceuticals, Inc.
Competitors
- DURECT Corporation
- KemPharm, Inc.
- Icure Pharmaceutical Inc.
- Zosano Pharma Corp.
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 24 Sep, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.